Stephen Hansen

6 days ago | biocentury.com | Stephen Hansen

ARTICLE | BioCentury CommentaryWith U.S. institutions under strain, Europe must act decisively to support innovation and secure a bigger role in biotech’s future By Stephen Hansen, Director of Biopharma IntelligenceIn the 18 years I’ve been covering the biopharma industry, FDA and NIH have always been the unquestioned gold standard for regulating the sector and fueling the basic research necessary to advance new, innovative therapeutics.

6 days ago | biocentury.com | Stephen Hansen

ARTICLE | BioCentury CommentaryWith U.S. institutions under strain, Europe must act decisively to support innovation and secure a bigger role in biotech’s future By Stephen Hansen, Director of Biopharma IntelligenceIn the 18 years I’ve been covering the biopharma industry, FDA and NIH have always been the unquestioned gold standard for regulating the sector and fueling the basic research necessary to advance new, innovative therapeutics.

1 week ago | biocentury.com | Stephen Hansen

DATA GRAPHICS | Data ByteCompounded GLP-1s impact 1Q25 sales growth By Stephen Hansen, Director of Biopharma IntelligenceFor the second year in a row, Novo’s semaglutide franchise got off to a slow start. In 1Q25, sales of the pharma’s three GLP-1R agonist formulations — Ozempic, Wegovy and Rybelsus — declined quarter-over-quarter, as reported in DKK. However, Ozempic sales were up slightly in U.S. dollars (see Chart).

1 week ago | biocentury.com | Stephen Hansen

ARTICLE | FinanceHow the corporate VC is evolving its portfolio strategy By Stephen Hansen, Director of Biopharma Intelligence Boehringer Ingelheim Venture Fundis sharpening its approach as it continues to seek investments that could be of strategic interest to the German pharma in the long term. The fund’s dual focus on breakthrough therapeutics in non-core areas and novel modalities within core areas had skewed toward the former. Now, new leadership aims to bring the two back into balance.

3 weeks ago | biocentury.com | Stephen Hansen

DATA GRAPHICS | Data ByteEarly data on par with Roche, Viking programs By Stephen Hansen, Director of Biopharma IntelligenceThe latest GLP-1 data from Ascletis, while early, puts the biotech’s oral small molecule firmly in the mix for best in class when it comes to efficacy in obesity. Ascletis Pharma Inc. (HKEX:1672) rose 24% on Monday after announcing four-week data from the Phase Ib multiple-ascending dose trial for ASC30 in obese patients that showed up to 6.5% placebo-adjusted weight loss.